Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | BACE1 | P56817 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.49 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475389 | 1.00 | L3MBTL1 (0.73) | L3MBTL1LMNACYP1A2BACE1KDM4E | |
| SCHEMBL8066981 | 0.91 | LMNA (0.82) | L3MBTL1LMNACYP1A2BACE1KDM4E | |
| SCHEMBL423891 | 0.86 | L3MBTL1 (0.71) | L3MBTL1LMNACYP1A2BACE1KDM4E | |
| SCHEMBL17787233 | 0.85 | L3MBTL1 (0.59) | L3MBTL1LMNACYP1A2BACE1KDM4E | |
| SCHEMBL5391424 | 0.85 | L3MBTL1 (0.59) | L3MBTL1LMNACYP1A2BACE1KDM4E | |
| SCHEMBL15483502 | 0.82 | L3MBTL1 (0.56) | L3MBTL1LMNACYP1A2BACE1KDM4E | |
| SCHEMBL8273082 | 0.82 | L3MBTL1 (0.56) | L3MBTL1LMNACYP1A2BACE1KDM4E | |
| SCHEMBL11352364 | 0.80 | L3MBTL1 (0.55) | L3MBTL1LMNACYP1A2BACE1KDM4E | |
| SCHEMBL29502790 | 0.77 | CYP1A2 (1.00) | L3MBTL1LMNACYP1A2BACE1KDM4E | |
| SCHEMBL1088580 | 0.77 | CYP1A2 (0.69) | L3MBTL1LMNACYP1A2BACE1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181105-B1 | N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL)-3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2015-04-29 | — | — | EP | disclosed |
| US-8497286-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| EP-2420491-B1 | 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8383650-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-20130005770-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2013-01-03 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| EP-2181105-A1 | N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL)-3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS | Novartis Ag (CH) | 2010-05-05 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| WO-2009000811-A1 | N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL)-3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2008-12-31 | — | — | WO | disclosed |
| US-20080319018-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| EP-1968940-A1 | 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| WO-1995013273-A1 | ASYMMETRIC SYNTHESIS OF (S)-(-)-6-CHLORO-4-CYCLOPROPYL-3,4-DIHYDRO-4-[(2-PYRIDYL)ETHYNYL]-2(1H)-QUINAZOLINONE | MERCK & CO., INC. (US) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | L3MBTL1 3031/4885LMNA 1594/4885CYP1A2 239/4885 |
| US-20080319018-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | L3MBTL1 1772/4885LMNA 2118/4885CYP1A2 181/4885 |
| US-20130005770-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | L3MBTL1 1772/4885LMNA 2118/4885CYP1A2 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.